All News

RheumNow Podcast square

Believing is Doing (1.21.2022)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from this past week on RheumNow.com. These reports are about better outcomes in Lupus; fewer Gout flares with T2T and the power of belief. 

Read Article
hands.stiff2_.jpg

Referral Rules for At-Risk Inflammatory Arthritis

Jack Cush, MD

A prospective primary care study of patients at-risk for inflammatory arthritis (IA) showed that progression to IA was most likely in those with high anti-CCP antibody titers levels and involvement of the hands/feet/ IA.

Read Article
RheumNow Podcast square

The Overpricing of Drugs (1.14.2022)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. This week we discuss amputations, a $57 billion RA market, an FDA approved drug for Cat arthritis and drug that works in Sjogren's.

Read Article
COVID,vaccinate,injection,green

COVAX Registry: Safety of COVID-19 Vaccines in Rheum Patients

Jack Cush, MD

The EULAR Coronavirus Vaccine (COVAX) physician-reported registry has shown that the use of COVID-19 vaccines in people with inflammatory/autoimmune rheumatic and musculoskeletal disease (I-RMD) is effective, safe, and well tolerated.

Read Article
JIA,knee,synovitis

What Can JIA Patients Expect 18 Years In?

MedPage Today

Follow-up in a Scandinavian cohort of juvenile idiopathic arthritis (JIA) patients that began in 1997-2000 revealed a number of surprises, a new study indicated.

Read Article
pregnancy,doctor,consult

COVID-19 in Pregnant Rheumatic Women

Jack Cush, MD

The Global Rheumatology Alliance (GRA) has studied the outcomes of women with rheumatic disease who were pregnant at the time of infection with coronavirus disease 2019 (COVID-19).

Read Article
2021,year

2021 Rheumatology Year in Review

Jack Cush, MD

Our top 10 list of advances, game-changers, worries and those better medical practices that evolved during 2021.

Read Article
We are excited to announce that Dr. Janet Pope will be joining us at RheumNow Live, leading a presentation on Drug Cycling vs Switching in RA. Join the discussion on March 19-20, on site or virtually! https://t.co/RfWz53vem3 https://t.co/9n1UzFrkVb

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Infliximab treatment of RMD/IMIDs by targeting drug levels (therapeutic drug monitoring) was superior to usual care in study with more sustained Dz control without worsening in 458 IMID pts Rx for 52 weeks (TDM 74% vs 70% standard Rx) https://t.co/KsnQxYXHkI

Links:

Dr. John Cush RheumNow ( View Tweet)

GWAS study in RA used to develop polygenic risk score (PRS) for Xray progression (training set = 500 and validated testing set= 740). Risk factors for severe XRAY progr = PRS (P=0.00019), female (P=0.0033), ACPA (P=0.0023), BMI (P=0.031) https://t.co/dwDSnTFUqs

Links:

Dr. John Cush RheumNow ( View Tweet)

Referral Rules for At-Risk Inflammatory Arthritis https://t.co/p1sBNSmWF5 https://t.co/tk29UNPYdi

Links:

Dr. John Cush RheumNow ( View Tweet)
Dr. Peter Nigrovic asserts the division between pediatric and adult arthritis is senseless and has no firm biologic basis. Instead we should consider pts as sero- positive or negative, Systemci or Spondyloarthropathy. @UTSWRheum https://t.co/zx5oQmUQ6Y
Dr. John Cush RheumNow ( View Tweet)
192 early arthritis & 693 early arthralgia underwent the MTP-squeeze-test (MTPsqT) & MRI. Synovitis & intermetatarsal bursitis (IMB) were assoc w/ MTPsqT. In EA, MTPsqT +, 79% had synovitis or IMB: 12% synovitis, 15% IMB & 52% had both. https://t.co/Ojwb8KkmLu

Links:

Dr. John Cush RheumNow ( View Tweet)

Register for RheumNow Live, March 19-20, 2022. You can attend RheumNow Live in person in Irving, Texas - or, the comfort of your own home or office. You can also receive CME credit! https://t.co/c7oLLCllM8 https://t.co/EGCGFilnVv

Links:

Dr. John Cush RheumNow ( View Tweet)
Why Are Physicians Silent About Outrageous Drug Prices? https://t.co/hLrUFCiKwm https://t.co/ZgRoW9Duo6

Links:

Dr. John Cush RheumNow ( View Tweet)
COVAX Registry: Safety of COVID-19 Vaccines in Rheum Patients  https://t.co/MrywKZKcIV https://t.co/QgajVPdesg

Links:

Dr. John Cush RheumNow ( View Tweet)
Register for RheumNow Live, March 19-20, 2022. You can attend RheumNow Live in person in Irving, Texas - or, the comfort of your own home or office. You can also receive CME credit! https://t.co/fYyV75vAWm https://t.co/zOpCbBrzHJ

Links:

Dr. John Cush RheumNow ( View Tweet)
The global rheumatoid arthritis drugs market size was valued at $57,929 million in 2019, and is projected to reach $62,935 million by 2027. https://t.co/hQTDc0ajdN

Links:

Dr. John Cush RheumNow ( View Tweet)

ICYMI: Infectious mimics of #RA include viruses (Parvo B19, HBV, HCV, HIV, Chikungunya alphaviruses) mycobacterial infections (Poncet's dz, TB, leprosy), bacterial arthritis, brucellosis and Lyme disease. https://t.co/3FOydnsj1V

Links:

Dr. John Cush RheumNow ( View Tweet)

Register for RheumNow Live, March 19-20, 2022. You can attend RheumNow Live in person in Irving, Texas - or, the comfort of your own home or office. You can also receive CME credit! https://t.co/cb787PiX5v https://t.co/ChAqBRCh7c

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×